Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
Open Access
- 1 March 2019
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 615-629
Abstract
Background: Batefenterol is a novel bifunctional muscarinic antagonist β2-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose–response of batefenterol and select a dose for Phase III development. Patients and methods: Patients aged ≥40 years with COPD and FEV1 ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300, or 600 µg, placebo, or umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg once daily. The primary and secondary endpoints were weighted-mean FEV1 over 0–6 hours post-dose and trough FEV1, analyzed by Bayesian and maximum likelihood estimation Emax of dose–response modeling, respectively, on day 42. Results: In the intent-to-treat population (N=323), all batefenterol doses demonstrated statistically and clinically significant improvements from baseline vs placebo in the primary and secondary endpoints (191.1–292.8 and 182.2–244.8 mL, respectively), with a relatively flat dose–response. In the subgroup reversible to salbutamol, there were greater differences between batefenterol doses. Lung function improvements with batefenterol ≥150 µg were comparable with those with UMEC/VI. Batefenterol was well tolerated and no new safety signals were observed. Conclusion: Batefenterol 300 µg may represent the optimal dose for Phase III studies.Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespiratory Medicine, 2013
- Prevalence and COPD Phenotype for a Suboptimal Peak Inspiratory Flow Rate against the Simulated Resistance of the Diskus ® Dry Powder InhalerJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2013
- A new class of bronchodilator improves lung function in COPD: a trial with GSK961081European Respiratory Journal, 2013
- The Risks and Benefits of Indacaterol — The FDA's ReviewNew England Journal of Medicine, 2011
- Inspiratory flow rates at different levels of resistance in elderly COPD patientsEuropean Respiratory Journal, 2007
- Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPDChest, 2006
- Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEuropean Respiratory Journal, 2005
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- In Vitro Aerosol Performance and Dose Uniformity between the Foradile ® Aerolizer ® and the Oxis ® Turbuhaler ®Journal of Aerosol Medicine, 2001
- A Critical Comparison of the Dose Delivery Characteristics of Four Alternative Inhalation Devices Delivering Salbutamol: Pressurized Metered Dose Inhaler, Diskus Inhaler, Diskhaler Inhaler, and Turbuhaler InhalerJournal of Aerosol Medicine, 1999